Detection of Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors Exposed to Cisplatin-based Chemotherapy and Bone Marrow Transplant
Status: Terminated
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY
Late subclinical cardiovascular disease in testicular cancer survivors exposed to cisplatin-based chemotherapy and bone marrow transplant
Eligibility
Participation Requirements
Sex: Male
Minimum Age: 18
Maximum Age: 99
Healthy Volunteers: f
View:
• Patients \>18 years of age
• Patients will be recruited only if cancer-free at clinical evaluation time.
• For the cases a confirmed TC diagnosis who received one or more cycles of CBCT-based chemotherapies (CBCT group, Arm 2)
• For the cases with a confirmed TC diagnosis who received one or more cycles of CBCT-based chemotherapies and underwent BMT for relapsed refractory disease (CBCT \& BMT group, Arm 3).
• For the comparison cohort, biopsy-proven TC patients who had surgery for or surveillance of their testicular cancer and never received CBCTCBCT or BMT (surgical/surveillance, Arm 1)
Locations
United States
Indiana
Indiana University
Indianapolis
Time Frame
Start Date: 2022-10-11
Completion Date: 2024-12-04
Participants
Target number of participants: 31
Treatments
Surgical/Surveillance
TCS cured with surgical resection and surveillance (surgical/surveillance, Arm 1)
Cisplatin-based chemotherapy (CBCT)
TCS treat with one or more lines of cisplatin-based chemotherapy
Cisplatin-based chemotherapy and Bone Marrow Transplant (CBCT/BMT)
TCS treat with one or more lines of cisplatin-based chemotherapy, and who have undergone bone marrow transplant
Related Therapeutic Areas
Sponsors
Collaborators: National Institutes of Health (NIH)
Leads: Indiana University